Role of fractionated radiotherapy in patients with hemangioma of the cavernous sinus.
- Author:
Sunmin PARK
1
;
Sang Min YOON
;
Sumin LEE
;
Jin hong PARK
;
Si Yeol SONG
;
Sang wook LEE
;
Seung Do AHN
;
Jong Hoon KIM
;
Eun Kyung CHOI
Author Information
- Publication Type:Original Article
- Keywords: Hemangioma; Cavernous sinus; Radiotherapy
- MeSH: Cavernous Sinus*; Cranial Nerve Diseases; Female; Follow-Up Studies; Hemangioma*; Humans; Optic Nerve Diseases; Radiotherapy*; Retrospective Studies; Tumor Burden
- From:Radiation Oncology Journal 2017;35(3):268-273
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: We performed this retrospective study to investigate the outcomes of patients with hemangioma of the cavernous sinus after fractionated radiotherapy. MATERIALS AND METHODS: We analyzed 10 patients with hemangioma of the cavernous sinus who were treated with conventional radiotherapy between January 2000 and December 2016. The median patient age was 54 years (range, 31–65 years), and 8 patients (80.0%) were female. The mean hemangioma volume was 34.1 cm3 (range, 6.8–83.2 cm3), and fractionated radiation was administered to a total dose of 50–54 Gy with a daily dose of 2 Gy. RESULTS: The median follow-up period was 6.8 years (range, 2.2–8.8 years). At last follow-up, the volume of the tumor had decreased in all patients. The average tumor volume reduction rate from the initial volume was 72.9% (range, 18.9–95.3%). All 10 of the cranial neuropathies observed before radiation therapy had improved, with complete symptomatic remission in 9 cases (90%) and partial remission in 1 case (10%). No new acute neurologic impairments were reported after radiotherapy. One probable compressive optic neuropathy was observed at 1 year after radiotherapy. CONCLUSION: Fractionated radiotherapy achieves both symptomatic and radiologic improvements. It is a well-tolerated treatment modality for hemangiomas of the cavernous sinus.
